Citizen petitions allow members of the general public to ask the agency to refrain from approving a generic drug or biosimilar over potential health concerns. However, the FDA said most petitions they receive do not raise valid scientific concerns and believes they are filed by drug companies to delay approval of competing medicines.
Michael Carrier, a professor at Rutgers University School of Law in New Brunswick, N.J., conducted an analysis of the petitions and found brand name drugmakers filed 92 percent of citizen petitions between 2011 and 2015. The FDA denied more than nine out of every 10 petitions filed, reports STAT.
The FDA’s final rule, effective Jan. 9, will limit unnecessary delays in the approval of generic and biosimilar drugs unless the delay is crucial to protect public health, according to RAPS.
The view the final rule in its entirety, click here.
More articles on supply chain:
J.B. Hunt to add hundreds of trucks next year despite industry slowdown: 3 takeaways
FDA may allow medical companies to promote drugs, devices for off-label uses
Nuclear reactor shut down threatens supply of radioactive material for medical imaging
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
